文献速递核素与放射性配体治疗肿瘤 PET/CT

AB001(靶向前列腺特异性膜抗原的²¹²Pb放射性配体)在转移性去势抵抗性前列腺癌患者中的首次人体0期研究

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-05-01

在3例进展性转移性去势抵抗性前列腺癌患者中开展0期试验,单次静脉注射微量AB001(9.4 ± 0.3 MBq),用γ相机和SPECT/CT评估生物分布与病灶摄取。AB001给药安全,γ相机成像可行,仅1个病灶显示明确靶向摄取,血液分析提示药物注射后稳定,全身探头测量有效半衰期为8小时。

要点

  • AB001单次微量9.4 ± 0.3 MBq静脉注射安全,无注射相关并发症或随访期不良反应。
  • γ相机成像在微量水平可行,仅1个高PSMA表达病灶(腹膜后腔静脉旁淋巴结,短径11 mm)显示摄取。
  • 血液分析提示AB001注射后稳定,全身探头测量有效半衰期为8小时。

核心结论

  • 基于²¹²Pb的放射性配体AB001可安全用于转移性去势抵抗性前列腺癌患者。
  • AB001的γ相机成像在微量水平即具可行性,并展示了转移灶靶向,尽管仅1个病灶可见。
  • AB001良好的生物分布和清除特征鼓励进一步临床研究。

研究设计与样本

  • 0期试验纳入3例进展性转移性去势抵抗性前列腺癌患者,美国东部肿瘤协作组体能状态评分为1,前列腺特异性抗原水平分别为0.44、0.75和15 µg/L。
  • 所有患者均有至少3个PSMA表达转移灶,PSMA PET上SUVmax范围为10.1-77.4。
  • 每例患者静脉注射微量AB001 9.4 ± 0.3 MBq,计划给药后1-3小时和16-24小时行平面γ相机和SPECT/CT成像。
  • 用NaI探头测量评估全身清除,测定全血和血浆中²¹²Pb活度以研究血液清除和配体体内稳定性,随访28天安全性、耐受性和疗效生物标志物(前列腺特异性抗原、碱性磷酸酶)。

主要发现

  • AB001在PSMA表达最高病灶(腹膜后腔静脉旁淋巴结转移,短径11 mm)的摄取在SPECT上可见。
  • 其他转移灶的AB001摄取未清晰显示,可能因这些转移灶在PSMA PET上PSMA表达较低,结合AB001微量给药和成像系统限制。
  • 肾脏、含内容物的膀胱和肝脏的AB001摄取可与邻近组织清晰区分,血池内容可见,唾液腺未显影。
  • 血液分析提示AB001注射后稳定,全身探头测量显示有效半衰期为8小时。
  • 无AB001注射相关并发症或随访期不良反应;作为0期研究预期,前列腺特异性抗原和碱性磷酸酶评估未显示治疗效应迹象。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • AB001摄取仅1个病灶可见,其他转移灶摄取未清晰显示,可能因这些转移灶PSMA表达较低、AB001微量给药及成像系统限制。
  • 作为0期研究,前列腺特异性抗原和碱性磷酸酶评估未显示治疗效应迹象。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AB001, a prostate-specific membrane antigen (PSMA)-targeted small molecule labeled with the in vivo-generating α-emitter 212Pb, was investigated in a phase 0 trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary objective was to explore the feasibility of γ-camera imaging to assess biodistribution and uptake in metastatic lesions. Methods: Three patients with progressive mCRPC and Eastern Cooperative Oncology Group performance status 1 were included, having prostate-specific antigen levels of 0.44, 0.75, and 15 µg/L. All had at least 3 PSMA-expressing metastatic lesions, with an SUVmax range of 10.1-77.4 on PSMA PET. Each patient received a microdose of 9.4 ± 0.3 MBq of AB001 intravenously. Planar γ-camera and SPECT/CT imaging was scheduled 1-3 h and 16-24 h after administration. Whole-body clearance was assessed with NaI probe measurements. Activity of 212Pb in whole blood and plasma was measured to investigate clearance from blood and in vivo stability of the ligand. Safety, tolerability, and efficacy biomarkers (prostate-specific antigen, alkaline phosphatase) were followed for 28 d. Results: AB001 uptake in the lesion with the highest PSMA expression, a retrocaval lymph node metastasis with a short-axis diameter of 11 mm, was visualized on SPECT. Uptake of AB001 was not clearly demonstrated for other metastatic lesions, possibly because of the lower PSMA expression of these metastases on PSMA PET, combined with the administered AB001 microdose and imaging system limitations. Kidney, urinary bladder with contents, and liver uptake of AB001 were clearly distinguishable from adjacent tissue, and the blood pool content was seen. Salivary glands were not visualized. Blood analyses indicated stability of AB001 after injection, and whole-body probe measurements demonstrated an effective half-life of 8 h. There were no complications related to injection of AB001 or adverse reactions during follow-up. As expected for a phase 0 study, there was no indication of therapeutic effects as assessed by prostate-specific antigen and alkaline phosphatase. Conclusion: The 212Pb-based radioligand AB001 was safely administered to mCRPC patients. γ-camera imaging of AB001 was feasible, even at a microdose, and demonstrated metastatic targeting, albeit for only 1 lesion. The promising biodistribution and clearance encourage further clinical investigation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Berner K, Hernes E, Kvassheim M, et al. First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025. PMID: 40081958. doi:10.2967/jnumed.124.269299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。